Form 4: Corvus Pharmaceuticals Director Ian Clark Granted Stock Options

Corvus Pharmaceuticals, Inc. Director Ian T. Clark was granted 15,000 stock options with an exercise price of $4.24, vesting fully on the earlier of the first anniversary of the grant date or the 2026 Annual Meeting.

Summary

• Ian T. Clark, a Director of Corvus Pharmaceuticals, Inc. (CRVS), was granted 15,000 stock options.
• The options have an exercise price of $4.24 per share.
• The grant date for these options was June 12, 2025.
• The options are exercisable as of June 12, 2025, and expire on June 12, 2035.
• The underlying shares subject to the option will vest and become exercisable as to 100% of the total number of shares on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It is a routine compensation event and does not indicate any negative operational or financial issues.

Positives

• The grant of stock options to Director Ian T. Clark aligns his financial interests with those of the company's shareholders, incentivizing long-term performance.
• The vesting schedule encourages continuous service and commitment from the director.

Future Outlook

The stock options granted to Director Ian T. Clark are set to vest 100% on the earlier of the first anniversary of the grant date (June 12, 2026) or the date of the 2026 Annual Meeting of stockholders, contingent on his continuous service as a director.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain talent, and to align the interests of directors with those of shareholders. This particular grant is a routine compensation event for a director.

Comparison to Industry Standards

• The grant of stock options as a component of director compensation is a standard practice across various industries, including biotechnology, aligning director incentives with long-term shareholder value creation.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is typical for director equity grants, promoting retention and continued oversight.

Corporate Governance

Related Party Transactions

• The grant of stock options to Ian T. Clark, a Director of Corvus Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the date of the 2026 Annual Meeting of Corvus Pharmaceuticals' stockholders, assuming continuous service.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant